STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS

Key results of 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia. Paris, France, June 7, 2006 – Sanofi–aventis announced today key trial results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, regarding the use of Taxotere® (docetaxel) regimens in the treatment of non small cell lung cancer (NSCLC), head and neck cancer and metastatic and adjuvant breast cancer. Läs hela pressmeddelandet i det bifogade dokumentet.